Evidence map›Paper›PMID 38004600›Full record

ReviewPharmaceutics2023

Advances in Polymeric Micelles: Responsive and Targeting Approaches for Cancer Immunotherapy in the Tumor Microenvironment.

Lichun Cheng, Jiankun Yu, Tangna Hao, Wenshuo Wang, Minjie Wei, Guiru Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lichun ChengDepartment of Pharmacy, The Second Hospital of Dalian Medical University, Dalian 116027, China.
Jiankun YuSchool of Pharmacy, China Medical University, Shenyang 110122, China.
Tangna HaoDepartment of Pharmacy, The Second Hospital of Dalian Medical University, Dalian 116027, China.
Wenshuo WangDepartment of Pharmacy, The Second Hospital of Dalian Medical University, Dalian 116027, China.
Minjie WeiSchool of Pharmacy, China Medical University, Shenyang 110122, China.
Guiru LiDepartment of Pharmacy, The Second Hospital of Dalian Medical University, Dalian 116027, China.
China Medical University · CNSecond Affiliated Hospital of Dalian Medical University · CNDalian Medical University · CN

Funding

China Postdoctoral Science Foundation under Grant 2019M651179Dalian Traditional Chinese Medicine Scientific Research Project 21Z12008Natural Science Foundation Committee of China under Grant 81,703,440
6 · The paper itself

Abstract

In recent years, to treat a diverse array of cancer forms, considerable advancements have been achieved in the field of cancer immunotherapies. However, these therapies encounter multiple challenges in clinical practice, such as high immune-mediated toxicity, insufficient accumulation in cancer tissues, and undesired off-target reactions. To tackle these limitations and enhance bioavailability, polymer micelles present potential solutions by enabling precise drug delivery to the target site, thus amplifying the effectiveness of immunotherapy. This review article offers an extensive survey of recent progress in cancer immunotherapy strategies utilizing micelles. These strategies include responsive and remodeling approaches to the tumor microenvironment (TME), modulation of immunosuppressive cells within the TME, enhancement of immune checkpoint inhibitors, utilization of cancer vaccine platforms, modulation of antigen presentation, manipulation of engineered T cells, and targeting other components of the TME. Subsequently, we delve into the present state and constraints linked to the clinical utilization of polymeric micelles. Collectively, polymer micelles demonstrate excellent prospects in tumor immunotherapy by effectively addressing the challenges associated with conventional cancer immunotherapies.

Indexed as

cancer immunotherapypolymeric micellesresponsive delivery systemstargeted drug deliverytumor microenvironment

Identifiers

PMID38004600
PMCPMC10675796
OpenAlexW4388630090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.